Individuals with pulmonary fibrosis could develop more serious complications if infected with COVID-19, and those awaiting organ transplantation and other surgical interventions may face delays because of the pandemic.
Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
Recent studies have led to important insights regarding the role of viruses in asthma pathogenesis and exacerbations, as well as mediating factors involved in these processes.
Patients with COVID-19 who also have poor baseline health and/or obesity are more likely to demonstrate impaired respiratory muscle performance.
Clinicians have proposed a system-wide response plan for the delivery of high-quality palliative care across a continuum of conventional, contingency, and crisis capacity scenarios during the COVID-19 pandemic.
Despite significant advances in asthma treatment in the past decades, the disease is still poorly controlled in an estimated 50% of patients.
Physicians and hospitals have urged the public to seek immediate medical care when needed, with reassurance regarding sound infection control practices that hospitals have implemented in light of the COVID-19 pandemic.
Specialists emphasized that although shared ventilation may be necessary in times of crisis, innovative alternatives should be used to avoid such extreme measures during the COVID-19 pandemic.
In a general population of patients with latent TB infection (including patients with and without HIV), studies have confirmed the superior safety profile of treatment with rifampicin vs isoniazid.
Pulmonary rehabilitation programs represent a key component in the management of patients with chronic obstructive pulmonary disease.
